Why the Standard Heart Failure Blood Test Misses Half the Cases — and How to Fix It
NT-proBNP, the go-to peptide biomarker for heart failure, often gives misleading results in HFpEF patients, and this review proposes a structured pathway combining adjusted thresholds with imaging to improve diagnosis.
Quick Facts
What This Study Found
NT-proBNP is a widely used biomarker for heart failure, but its diagnostic accuracy in HFpEF (heart failure with preserved ejection fraction) is compromised by age, obesity, atrial fibrillation, and kidney dysfunction. This review proposes a structured clinical pathway that combines adjusted NT-proBNP thresholds, clinical scoring systems like the H2FPEF and HFA-PEFF scores, and multimodal imaging to improve diagnosis of this commonly missed condition.
HFpEF accounts for approximately 50% of all heart failure cases globally but remains one of the most underdiagnosed cardiovascular conditions because its symptoms mimic those of other age-related conditions.
Key Numbers
~50% of global HF cases are HFpEF · Evidence compiled from 2022-2025 · Confounders: age, obesity, atrial fibrillation, renal dysfunction
How They Did This
Narrative review critically analyzing recent evidence from 2022-2025 on NT-proBNP's diagnostic role in HFpEF. The authors propose a stepwise clinical pathway integrating adjusted biomarker thresholds, validated scoring systems, and imaging modalities.
Why This Research Matters
Half of all heart failure patients have HFpEF, yet many go undiagnosed because the standard biomarker (NT-proBNP) can be misleading in the very populations most affected — older adults with obesity, kidney problems, or irregular heart rhythms. A structured diagnostic approach could catch thousands of missed cases and connect patients to treatment earlier.
The Bigger Picture
NT-proBNP is one of the most important peptide biomarkers in medicine, used millions of times annually to diagnose heart failure. But as the understanding of HFpEF has evolved, it's become clear that a single biomarker cutoff isn't sufficient. This review reflects a broader trend in peptide biomarker research toward context-dependent interpretation rather than one-size-fits-all thresholds.
What This Study Doesn't Tell Us
As a narrative review published in Cureus (an open-access journal with lighter peer review), the evidence synthesis may not be as rigorous as a systematic review. The proposed clinical pathway has not been prospectively validated. The abstract doesn't detail how studies were selected or assessed for quality.
Questions This Raises
- ?Would prospective validation of the proposed clinical pathway show improved HFpEF detection rates compared to standard NT-proBNP interpretation?
- ?Could machine learning algorithms that integrate NT-proBNP with patient demographics and comorbidities outperform fixed adjusted thresholds?
- ?Are there emerging peptide biomarkers that could complement NT-proBNP specifically for HFpEF diagnosis?
Trust & Context
- Key Stat:
- ~50% of heart failure cases HFpEF accounts for roughly half of all heart failure globally but remains one of the most underdiagnosed cardiovascular conditions
- Evidence Grade:
- This is a narrative review compiling evidence from 2022-2025. It proposes a clinical pathway but does not present new clinical data or use systematic review methodology. Published in Cureus, which has a less rigorous peer review process than top cardiology journals.
- Study Age:
- Published in 2025, this review incorporates the most recent evidence (2022-2025) on NT-proBNP utility in HFpEF, making it highly current.
- Original Title:
- Optimizing the Use of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) in the Diagnosis of Heart Failure With Preserved Ejection Fraction (HFpEF): A Clinical Pathway Approach to an Underdiagnosed Entity.
- Published In:
- Cureus, 17(12), e99161 (2025)
- Authors:
- Gupta, Mukulesh, Kumar, Dinesh(3), Gupta, Tuhina
- Database ID:
- RPEP-11226
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is NT-proBNP and why is it tested?
NT-proBNP is a peptide fragment released into the blood when the heart muscle is stretched or under stress. Doctors use it as a blood test to help diagnose heart failure — higher levels typically indicate the heart is struggling. It's one of the most commonly ordered cardiac biomarkers worldwide.
Why does NT-proBNP miss so many HFpEF cases?
Several common conditions interfere with NT-proBNP levels. Obesity can falsely lower levels, kidney disease can falsely raise them, and both aging and atrial fibrillation alter the results. Since HFpEF patients are often older adults with multiple health conditions, the standard cutoff values frequently lead to missed or incorrect diagnoses.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11226APA
Gupta, Mukulesh; Kumar, Dinesh; Gupta, Tuhina. (2025). Optimizing the Use of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) in the Diagnosis of Heart Failure With Preserved Ejection Fraction (HFpEF): A Clinical Pathway Approach to an Underdiagnosed Entity.. Cureus, 17(12), e99161. https://doi.org/10.7759/cureus.99161
MLA
Gupta, Mukulesh, et al. "Optimizing the Use of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) in the Diagnosis of Heart Failure With Preserved Ejection Fraction (HFpEF): A Clinical Pathway Approach to an Underdiagnosed Entity.." Cureus, 2025. https://doi.org/10.7759/cureus.99161
RethinkPeptides
RethinkPeptides Research Database. "Optimizing the Use of N-terminal Pro-B-Type Natriuretic Pept..." RPEP-11226. Retrieved from https://rethinkpeptides.com/research/gupta-2025-optimizing-the-use-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.